Table I.
Clinical features of TCGA set and three validation sets.
| Clinical factor | TCGA (n=154) | GSE13041 (n=191) | CGGA (n=128) | GSE74187 (n=60) |
|---|---|---|---|---|
| Age (years, mean ± SD) | 59.84±13.54 | 53.83±13.65 | 47.41±11.83 | – |
| Sex (male/female/−) | 99/54/1 | 116/74/1 | 62/39/27 | – |
| Chemotherapy (yes/no/−) | 44/91/19 | – | – | – |
| Drug therapy (yes/no/−) | 19/115/20 | – | – | – |
| Pharmaceutical therapy (yes/no/−) | 55/84/15 | – | – | – |
| Radiation therapy (yes/no/−) | 19/120/15 | – | – | – |
| Targeted molecular therapy (yes/no/−) | 18/116/20 | – | – | – |
| Progression free survival (yes/no) | – | – | – | 51/9 |
| Progression free survival months (mean ± SD) | – | – | – | 14.94±10.56 |
| Death (dead/alive) | 102/50 | 176/15 | 68/33 | 46/14 |
| Overall survival (months, mean ± SD) | 12.06±10.41 | 19.37±19.41 | 14.24±7.85 | 19.15±10.58 |
TCGA, The Cancer Genome Atlas; CGGA, Chinese Glioma Genome Atlas; SD, standard deviation; −, information unavailable.